CN105709204A - 一种改善脑功能的口服液及其制备方法 - Google Patents
一种改善脑功能的口服液及其制备方法 Download PDFInfo
- Publication number
- CN105709204A CN105709204A CN201610236591.1A CN201610236591A CN105709204A CN 105709204 A CN105709204 A CN 105709204A CN 201610236591 A CN201610236591 A CN 201610236591A CN 105709204 A CN105709204 A CN 105709204A
- Authority
- CN
- China
- Prior art keywords
- brain
- solution
- purified water
- cephalopin
- thing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003925 brain function Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940100688 oral solution Drugs 0.000 title abstract 6
- 210000004556 brain Anatomy 0.000 claims abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000008213 purified water Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 24
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 13
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 22
- 229960004756 ethanol Drugs 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 230000003292 diminished effect Effects 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 239000012065 filter cake Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 7
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 108090000526 Papain Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 238000005352 clarification Methods 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 238000005374 membrane filtration Methods 0.000 claims description 5
- 238000001728 nano-filtration Methods 0.000 claims description 5
- 229940055729 papain Drugs 0.000 claims description 5
- 235000019834 papain Nutrition 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000013517 stratification Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 229960001322 trypsin Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 210000005036 nerve Anatomy 0.000 abstract description 8
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 5
- 238000007670 refining Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种改善脑功能的口服液及其制备方法,所述改善脑功能的口服液由以下原料制备而成:总氨基酸浓度为500~1500mg/100ml的脑小分子肽溶液100ml、脑脂质物25~50mg、γ?氨基丁酸500~2000mg、α?亚麻酸100~500mg;其制备方法为:采用新鲜猪脑提取脑小分子肽溶液和脑脂质物,将提取得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为500~1500mg/100ml,每100ml稀释后的脑小分子肽溶液中加入脑脂质物25~50mg、γ?氨基丁酸500~2000mg、α?亚麻酸100~500mg制成本发明的口服液;本发明在新鲜猪脑提取和精制过程中充分的保留了营养修复神经所需的蛋白质和脂类物质,提取的脑小分子肽和脑脂质物制备的口服液具有更好的营养修复神经效果;营养更全面、易吸收、具有极大的推广价值。
Description
技术领域
本发明属于生物技术领域,涉及动物脑小分子肽和脑脂质物的酶解与提取技术,具体是一种改善脑功能的口服液及其制备方法。
背景技术
脑是人体神经中枢最高级的组成部分,支配着运动、感觉、思维、记忆、情绪等与日常生活与工作息息相关的功能,神经细胞是大脑的基本单元,大脑的记忆存储和对身体的指令功能是通过脑细胞之间的信号传递实现的,因此,神经细胞的营养与健康直接关系到大脑的功能,也直接关系着人的生活质量;脑内的神经细胞需要靠小分子肽来维持活性状态,神经传导、信息传递的化学物质——神经递质也是由脑小分子肽或其分解产物所构成,可以说脑小分子肽是维持大脑正常活动与功能的重要条件;活性脑脂质物包括磷脂类、糖脂类,可以促进脑细胞发育和神经髓鞘的形成,并保证其维持良好的功能,它们还是构成细胞膜的基本成分,负责神经细胞间信号的传递;大部分脑小分子肽和活性脑脂质物类产品都是由新鲜猪脑中经提取和精制获得,具有修复神经损伤,增强人脑功能发育,对神经系统疾病具有很好的治疗和保健功效,目前关于这两类物质的已公开制备方法中均将蛋白质或脂类其中之一作为废弃物被丢弃,是一种极大地浪费。
发明内容
本发明的目的在于提供一种修复神经效果好、营养大脑、改善脑功能的口服液及其制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种改善脑功能的口服液,由以下原料制备而成:总氨基酸浓度为500~1500mg/100ml的脑小分子肽溶液100ml、脑脂质物25~50mg、γ-氨基丁酸500~2000mg、α-亚麻酸100~500mg。
作为本发明进一步的方案:所述脑小分子肽溶液与脑脂质物的配比为100ml:25mg。
所述改善脑功能的口服液的制备方法,包括以下步骤:
1)取新鲜猪脑用纯化水洗净,去除表面的包膜和血管,加2~4倍无水乙醇胶体磨匀浆2~4次,溶出脂肪;
2)取步骤1)的匀浆液,减压过滤分别收集乙醇滤液和滤饼;
3)向步骤2)滤饼中加入4倍体积生理盐水,反复冻融3~5次,调节pH值到3.0,加入胃蛋白酶、胰蛋白酶和木瓜蛋白酶于37℃条件下水解5~8小时,获得酶解液;
4)调节步骤3)酶解液的pH值到7.5,5000转/分钟离心,得到澄清的上清液,用1KD-8KD的纳滤膜过滤,得到脑小分子肽溶液;
5)向步骤2)乙醇滤液中加入2倍体积的乙酸乙酯和1倍体积的纯化水,在37℃条件下,搅拌30min后静置分层;
6)取步骤5)中下层乙醇水相,加入纯化水调整乙醇浓度为60%,上样非极性大孔吸附树脂,吸附饱和后用纯化水洗涤2倍柱体积,用80%浓度的乙醇溶液洗脱,收集洗脱液;
7)将步骤6)中洗脱液在60℃条件下浓缩至原体积1/8时,加入2倍体积的预冷丙酮,沉淀6小时,经减压过滤和真空干燥,获得脑脂质物;
8)将步骤4)中得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为500~1500mg/100ml;
9)每100ml步骤8)稀释后的溶液中加入步骤7)得到的脑脂质物25~50mg、γ-氨基丁酸500~2000mg、α-亚麻酸100~500mg制成本发明的口服液。
作为本发明再进一步的方案:所述步骤9)中,脑脂质物的加入量为25mg。
与现有技术相比,本发明的有益效果是:本发明在新鲜猪脑提取和精制过程中充分的保留了营养修复神经所需的蛋白质和脂类物质,提取的脑小分子肽和脑脂质物制备的口服液具有更好的营养修复神经效果;同时本发明针对神经细胞的特点,提供了更全面的营养,包含人脑生长和修复所需要的三种结构性成分:小分子肽、脑脂质物和多烯酸,其中γ-氨基丁酸除了是大脑的营养物质,还是一种重要的抑制性神经递质,在修复受损神经的同时,稳定神经功能,起到标本兼治的作用,多烯酸的加入,增加了小分子肽、脑脂质物的吸收和在脑神经细胞的利用率;经过试验得出,本发明的口服液易吸收、营养大脑和修复神经效果明显,具有极大的推广价值。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种改善脑功能的口服液,由以下原料制备而成:总氨基酸浓度为500mg/100ml的脑小分子肽溶液100ml、脑脂质物25mg、γ-氨基丁酸500mg、α-亚麻酸100mg。
所述改善脑功能的口服液的制备方法,包括以下步骤:
1)取新鲜猪脑用纯化水洗净,去除表面的包膜和血管,加2倍无水乙醇胶体磨匀浆2次,溶出脂肪;
2)取步骤1)的匀浆液,减压过滤分别收集乙醇滤液和滤饼;
3)向步骤2)滤饼中加入4倍体积生理盐水,反复冻融3次,调节pH值到3.0,加入胃蛋白酶、胰蛋白酶和木瓜蛋白酶于37℃条件下水解5小时,获得酶解液;
4)调节步骤3)酶解液的pH值到7.5,5000转/分钟离心,得到澄清的上清液,用1KD-8KD的纳滤膜过滤,得到脑小分子肽溶液;
5)向步骤2)乙醇滤液中加入2倍体积的乙酸乙酯和1倍体积的纯化水,在37℃条件下,搅拌30min后静置分层;
6)取步骤5)中下层乙醇水相,加入纯化水调整乙醇浓度为60%,上样非极性大孔吸附树脂,吸附饱和后用纯化水洗涤2倍柱体积,用80%浓度的乙醇溶液洗脱,收集洗脱液;
7)将步骤6)中洗脱液在60℃条件下浓缩至原体积1/8时,加入2倍体积的预冷丙酮,沉淀6小时,经减压过滤和真空干燥,获得脑脂质物;
8)将步骤4)中得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为500mg/100ml;
9)每100ml步骤8)稀释后的溶液中加入步骤7)得到的脑脂质物25mg、γ-氨基丁酸500mg、α-亚麻酸100mg制成本发明的口服液。
实施例2
一种改善脑功能的口服液,由以下原料制备而成:总氨基酸浓度为1000mg/100ml的脑小分子肽溶液100ml、脑脂质物38mg、γ-氨基丁酸1250mg、α-亚麻酸300mg。
所述改善脑功能的口服液的制备方法,包括以下步骤:
1)取新鲜猪脑用纯化水洗净,去除表面的包膜和血管,加3倍无水乙醇胶体磨匀浆3次,溶出脂肪;
2)取步骤1)的匀浆液,减压过滤分别收集乙醇滤液和滤饼;
3)向步骤2)滤饼中加入4倍体积生理盐水,反复冻融4次,调节pH值到3.0,加入胃蛋白酶、胰蛋白酶和木瓜蛋白酶于37℃条件下水解6.5小时,获得酶解液;
4)调节步骤3)酶解液的pH值到7.5,5000转/分钟离心,得到澄清的上清液,用1KD-8KD的纳滤膜过滤,得到脑小分子肽溶液;
5)向步骤2)乙醇滤液中加入2倍体积的乙酸乙酯和1倍体积的纯化水,在37℃条件下,搅拌30min后静置分层;
6)取步骤5)中下层乙醇水相,加入纯化水调整乙醇浓度为60%,上样非极性大孔吸附树脂,吸附饱和后用纯化水洗涤2倍柱体积,用80%浓度的乙醇溶液洗脱,收集洗脱液;
7)将步骤6)中洗脱液在60℃条件下浓缩至原体积1/8时,加入2倍体积的预冷丙酮,沉淀6小时,经减压过滤和真空干燥,获得脑脂质物;
8)将步骤4)中得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为1000mg/100ml;
9)每100ml步骤8)稀释后的溶液中加入步骤7)得到的脑脂质物38mg、γ-氨基丁酸1250mg、α-亚麻酸300mg制成本发明的口服液。
实施例3
一种改善脑功能的口服液,由以下原料制备而成:总氨基酸浓度为1500mg/100ml的脑小分子肽溶液100ml、脑脂质物50mg、γ-氨基丁酸2000mg、α-亚麻酸500mg。
所述改善脑功能的口服液的制备方法,包括以下步骤:
1)取新鲜猪脑用纯化水洗净,去除表面的包膜和血管,加4倍无水乙醇胶体磨匀浆4次,溶出脂肪;
2)取步骤1)的匀浆液,减压过滤分别收集乙醇滤液和滤饼;
3)向步骤2)滤饼中加入4倍体积生理盐水,反复冻融5次,调节pH值到3.0,加入胃蛋白酶、胰蛋白酶和木瓜蛋白酶于37℃条件下水解8小时,获得酶解液;
4)调节步骤3)酶解液的pH值到7.5,5000转/分钟离心,得到澄清的上清液,用1KD-8KD的纳滤膜过滤,得到脑小分子肽溶液;
5)向步骤2)乙醇滤液中加入2倍体积的乙酸乙酯和1倍体积的纯化水,在37℃条件下,搅拌30min后静置分层;
6)取步骤5)中下层乙醇水相,加入纯化水调整乙醇浓度为60%,上样非极性大孔吸附树脂,吸附饱和后用纯化水洗涤2倍柱体积,用80%浓度的乙醇溶液洗脱,收集洗脱液;
7)将步骤6)中洗脱液在60℃条件下浓缩至原体积1/8时,加入2倍体积的预冷丙酮,沉淀6小时,经减压过滤和真空干燥,获得脑脂质物;
8)将步骤4)中得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为1500mg/100ml;
9)每100ml步骤8)稀释后的溶液中加入步骤7)得到的脑脂质物50mg、γ-氨基丁酸2000mg、α-亚麻酸500mg制成本发明的口服液。
上面对本专利的较佳实施方式作了详细说明,但是本专利并不限于上述实施方式,在本领域的普通技术人员所具备的知识范围内,还可以在不脱离本专利宗旨的前提下作出各种变化。
Claims (4)
1.一种改善脑功能的口服液,其特征在于:由以下原料制备而成:总氨基酸浓度为500~1500mg/100ml的脑小分子肽溶液100ml、脑脂质物25~50mg、γ-氨基丁酸500~2000mg、α-亚麻酸100~500mg。
2.根据权利要求1所述的改善脑功能的口服液,其特征在于,所述脑小分子肽溶液与脑脂质物的配比为100ml:25mg。
3.根据权利要求1所述的改善脑功能的口服液的制备方法,其特征在于,包括以下步骤:
1)取新鲜猪脑用纯化水洗净,去除表面的包膜和血管,加2~4倍无水乙醇胶体磨匀浆2~4次,溶出脂肪;
2)取步骤1)的匀浆液,减压过滤分别收集乙醇滤液和滤饼;
3)向步骤2)滤饼中加入4倍体积生理盐水,反复冻融3~5次,调节pH值到3.0,加入胃蛋白酶、胰蛋白酶和木瓜蛋白酶于37℃条件下水解5~8小时,获得酶解液;
4)调节步骤3)酶解液的pH值到7.5,5000转/分钟离心,得到澄清的上清液,用1KD-8KD的纳滤膜过滤,得到脑小分子肽溶液;
5)向步骤2)乙醇滤液中加入2倍体积的乙酸乙酯和1倍体积的纯化水,在37℃条件下,搅拌30min后静置分层;
6)取步骤5)中下层乙醇水相,加入纯化水调整乙醇浓度为60%,上样非极性大孔吸附树脂,吸附饱和后用纯化水洗涤2倍柱体积,用80%浓度的乙醇溶液洗脱,收集洗脱液;
7)将步骤6)中洗脱液在60℃条件下浓缩至原体积1/8时,加入2倍体积的预冷丙酮,沉淀6小时,经减压过滤和真空干燥,获得脑脂质物;
8)将步骤4)中得到脑小分子肽溶液加纯化水稀释到总氨基酸浓度为500~1500mg/100ml备用;
9)每100ml步骤8)稀释后的溶液中加入步骤7)得到的脑脂质物25~50mg、γ-氨基丁酸500~2000mg、α-亚麻酸100~500mg制成本发明的口服液。
4.根据权利要求3所述的改善脑功能的口服液的制备方法,其特征在于,所述步骤9)中,脑脂质物的加入量为25mg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610236591.1A CN105709204A (zh) | 2016-04-15 | 2016-04-15 | 一种改善脑功能的口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610236591.1A CN105709204A (zh) | 2016-04-15 | 2016-04-15 | 一种改善脑功能的口服液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105709204A true CN105709204A (zh) | 2016-06-29 |
Family
ID=56160344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610236591.1A Pending CN105709204A (zh) | 2016-04-15 | 2016-04-15 | 一种改善脑功能的口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105709204A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528603A (zh) * | 2021-07-09 | 2021-10-22 | 浙江省农业科学院 | 猪脑促增殖肽-脑中磷脂联产方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2302871C1 (ru) * | 2006-06-22 | 2007-07-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Средство, нормализующее функции головного мозга, и способ его получения |
CN101307346A (zh) * | 2007-05-18 | 2008-11-19 | 丹东双增食品开发(集团)有限公司 | 一种从畜牧动物脑组织中萃取健脑活性肽的方法 |
CN103191403A (zh) * | 2013-04-02 | 2013-07-10 | 黑龙江迪龙制药有限公司 | 一种脑蛋白水解物的制备方法 |
CN104511007A (zh) * | 2013-09-26 | 2015-04-15 | 西藏易明西雅医药科技股份有限公司 | 一种脑蛋白水解物的制备方法 |
CN105331665A (zh) * | 2015-12-09 | 2016-02-17 | 梁尚文 | 一种猪脑蛋白酶解制备脑多肽和脑小分子肽的方法 |
-
2016
- 2016-04-15 CN CN201610236591.1A patent/CN105709204A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2302871C1 (ru) * | 2006-06-22 | 2007-07-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Средство, нормализующее функции головного мозга, и способ его получения |
CN101307346A (zh) * | 2007-05-18 | 2008-11-19 | 丹东双增食品开发(集团)有限公司 | 一种从畜牧动物脑组织中萃取健脑活性肽的方法 |
CN103191403A (zh) * | 2013-04-02 | 2013-07-10 | 黑龙江迪龙制药有限公司 | 一种脑蛋白水解物的制备方法 |
CN104511007A (zh) * | 2013-09-26 | 2015-04-15 | 西藏易明西雅医药科技股份有限公司 | 一种脑蛋白水解物的制备方法 |
CN105331665A (zh) * | 2015-12-09 | 2016-02-17 | 梁尚文 | 一种猪脑蛋白酶解制备脑多肽和脑小分子肽的方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528603A (zh) * | 2021-07-09 | 2021-10-22 | 浙江省农业科学院 | 猪脑促增殖肽-脑中磷脂联产方法 |
CN113528603B (zh) * | 2021-07-09 | 2024-04-12 | 浙江省农业科学院 | 猪脑促增殖肽-脑中磷脂联产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10455849B2 (en) | Method for the preparation of a protein peptide, a protein peptide and use thereof | |
US20170267746A1 (en) | Techniques of preparing collagen active peptides | |
CA3012063A1 (en) | Walnut oligopeptide powder, preparation method and application thereof | |
EP0140134B1 (de) | Verfahren zur Herstellung eines biologisch aktiven Extraktes | |
CN106148445B (zh) | 一种新的谷氨酸提取工艺 | |
CN105420325B (zh) | 一种胎盘多肽的制备方法 | |
EP2589389B1 (en) | Method for producing a biologically active complex. biologically active protein/polypeptide complex | |
CN104745665A (zh) | 具有促进骨骼生长作用的胶原肽及其制备方法和应用 | |
KR101161634B1 (ko) | 특정 유리 아미노산 함량이 증진된 녹각 발효액의 제조방법 및 상기 방법으로 제조된 녹각 발효액 | |
CN105998072A (zh) | 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 | |
CN105709204A (zh) | 一种改善脑功能的口服液及其制备方法 | |
CN103695491B (zh) | L-谷氨酰胺的精制方法 | |
CN106086101A (zh) | 一种l‑色氨酸的发酵工艺 | |
BR112020023485A2 (pt) | Métodos para preparar um precursor de insulina humana recombinante ou análogo da mesma, insulina humana recombinante ou análogo da mesma e análogo de insulina acilado | |
CN106174494A (zh) | 一种组合物及其在制备健脑益智的产品中的应用 | |
CN101311273A (zh) | 生物合成的γ-氨基丁酸制剂及其制备方法 | |
CN108485856A (zh) | 一种黑枸杞干红的酿造方法 | |
EP2730586B1 (en) | Protein-polypeptide complex obtained from tissues of hoofed livestock embryos, process for preparing same and pharmaceutical composition | |
CN111690704A (zh) | 一种鹿茸多肽的制备方法及其应用 | |
CN116217663A (zh) | 一种雨生红球藻来源的抗氧化多肽kftpap、制备方法及应用 | |
CN104758919B (zh) | 一种小牛血清去蛋白注射液及其制备方法 | |
CN1775070A (zh) | 制备低糖蜂蜜的方法 | |
CN106667987A (zh) | γ‑氨基丁酸在制备肝脏保护药物制剂中的应用 | |
Eddy et al. | The isolation from autolyzed yeast of a crystalline substance melting at 223°, having the properties of a bios | |
JPS6041615A (ja) | コロニ−形成刺激因子の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160629 |